Physician profile
Steven Jay King
NPI 1861422396
$11,599.05
in general payments reported to CMS, 2019-2025
62 companies · $2,390 in 2025
The $2,390 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $981 · 2021: $1,645 · 2022: $1,608 · 2023: $1,670 · 2024: $2,494 · 2025: $2,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,553.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,773.84 | 2019-2025 | |
| Novo Nordisk INC | $938.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $750.69 | 2022-2025 | Azstarys |
| Lilly USA, LLC | $727.93 | 2019-2025 | Jardiance, Zepbound, Omvoh |
| Supernus Pharmaceuticals, INC. | $689.54 | 2021-2025 | Qelbree, Qelbree, Xyosted |
| Pfizer INC. | $633.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $628.14 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $609.65 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $567.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Ardelyx, INC. | $404.20 | 2022-2025 | Ibsrela |
| Csl Behring | $314.54 | 2019-2025 | Haegarda, Andembry |
| Ironshore Pharmaceuticals INC. | $280.91 | 2019-2024 | |
| Intra-Sana Laboratories | $248.31 | 2021-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Merck Sharp & Dohme LLC | $205.41 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Phathom Pharmaceuticals, INC. | $205.14 | 2024-2025 | Voquezna |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.30 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $176.47 | 2023-2025 | Symbravo, Auvelity |
| Otsuka America Pharmaceutical, INC. | $161.68 | 2024-2025 | Rexulti |
| Concordia Pharmaceuticals INC. | $160.90 | 2019 | |
| Neos Therapeutics, LP | $155.07 | 2020-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $143.19 | 2019-2025 | Dyanavel Xr |
| Horizon Therapeutics Plc | $143.17 | 2019-2023 | Krystexxa |
| Amgen INC. | $136.07 | 2022-2025 | Repatha, Amjevita, Repatha |
| Antares Pharma, INC. | $116.74 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $114.87 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $94.16 | 2025 | Jornay Pm |
| Redhill Biopharma INC. | $73.76 | 2020-2021 | |
| Adlon Therapeutics L.P. | $67.43 | 2019-2020 | |
| Ibsa Pharma INC. | $58.35 | 2020-2024 | Tirosint, Licart, Licart |
| Genentech USA, INC. | $51.82 | 2019-2020 | |
| Dexcom, INC. | $46.76 | 2024-2025 | Dexcom G6 Transmitter |
| Halozyme INC | $46.54 | 2023 | |
| Acadia Pharmaceuticals INC | $45.64 | 2023-2024 | Daybue |
| Abbott Laboratories | $43.31 | 2023-2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $43.08 | 2021-2022 | |
| Romark Laboratories, Lc | $35.93 | 2019 | |
| Tolmar, INC. | $33.77 | 2024-2025 | Jatenzo |
| Janssen Pharmaceuticals, INC | $30.78 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.72 | 2021 | |
| Zyla Life Sciences, INC. | $27.67 | 2020 | |
| Shield Therapeutics INC | $22.85 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.83 | 2024 | |
| Sanofi Pasteur INC. | $21.30 | 2020 | |
| Almatica Pharma LLC | $21.25 | 2024 | Loreev Xr |
| Upsher-Smith Laboratories LLC | $20.70 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.19 | 2024 | Zoryve |
| Kyowa Kirin, INC. | $19.24 | 2022 | |
| Sobi, INC | $18.75 | 2021 | |
| Medtronic, INC. | $18.58 | 2022 | |
| Amarin Pharma, INC. | $18.51 | 2019 | |
| Alfasigma USA, INC. | $18.40 | 2022 | |
| Genzyme Corporation | $17.34 | 2022 | |
| Seqirus USA INC | $17.30 | 2024 | Flucelvax |
| Corcept Therapeutics | $16.49 | 2024 | Korlym |
| Shire North American Group INC | $15.85 | 2019 | |
| Noven Therapeutics, LLC | $15.61 | 2024 | Xelstrym |
| Regeneron Healthcare Solutions, INC. | $15.52 | 2024 | Dupixent |
| Lundbeck LLC | $15.11 | 2025 | Rexulti |
| Dynavax Technologies Corporation | $14.08 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $13.71 | 2023 | Quviviq |
| Verrica Pharmaceuticals INC. | $13.67 | 2025 | Ycanth |
| Assertio Therapeutics, INC. | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.